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Angiotensin II type-1 receptor 
(AT1R) regulates expansion, 
differentiation, and functional 
capacity of antigen-specific  
CD8+ T cells
João Luiz Silva-Filho1,†, Celso Caruso-Neves1,2 & Ana Acacia Sá Pinheiro1,3
Angiotensin II (Ang II) and its receptor AT1 (AT1R), an important effector axis of renin-angiotensin system 
(RAS), have been demonstrated to regulate T-cell responses. However, these studies characterized Ang 
II and AT1R effects using pharmacological tools, which do not target only Ang II/AT1R axis. The specific 
role of AT1R expressed by antigen-specific CD8+ T cells is unknown. Then we immunized transgenic mice 
expressing a T-cell receptor specific for SIINFEKL epitope (OT-I mice) with sporozoites of the rodent 
malaria parasite Plasmodium berghei expressing the cytotoxic epitope SIINFEKL. Early priming events 
after immunization were not affected but the expansion and contraction of AT1R-deficient (AT1R−/−) 
OT-I cells was decreased. Moreover, they seemed more activated, express higher levels of CTLA-4, PD-1, 
LAG-3, and have decreased functional capacity during the effector phase. Memory AT1R−/− OT-I cells 
exhibited higher IL-7Rα expression, activation, and exhaustion phenotypes but less cytotoxic capacity. 
Importantly, AT1R−/− OT-I cells show better control of blood parasitemia burden and ameliorate mice 
survival during lethal disease induced by blood-stage malaria. Our study reveals that AT1R in antigen-
specific CD8+ T cells regulates expansion, differentiation, and function during effector and memory phases 
of the response against Plasmodium, which could apply to different infectious agents.
In the last decade, new components, local tissue production, and functions of the renin-angiotensin system (RAS) 
have been unraveled1–4. Our group and others have focused on describing the role of RAS effector molecules, 
especially angiotensin II (Ang II) and its receptor AT1 (AT1R), in the regulation of adaptive immune response5–21. 
Ang II has been proposed to have pro-inflammatory effects, via AT1R8–13,15–20, however the cellular mechanisms 
underlying the role of AT1R in the regulation of antigen-specific T cells in different pathologies are not clear yet.
It has been demonstrated that T cells possess a functional RAS and are capable of producing Ang II10–14,20,21. 
In these cells, Ang II promotes proliferation, differentiation, effector function, adhesion, migration, and 
acts as a co-stimulatory molecule important to T-cell activation, and all these effects are mediated by AT1R 
binding5–7,9–15,20,21. Importantly, AT1R expression is upregulated in T cells during activation in vitro and in vivo, 
for instance during the blood stage of Plasmodium berghei ANKA (PbA) infection, strengthening the impor-
tance of this receptor for T-cell response11–13,15. In this regard, AT1R is involved in the higher production of 
pro-inflammatory cytokines by CD4+ T cells and perforin by CD8+ T cells, and increased capacity to adhere 
and migrate through upregulation of adhesion molecules and chemokine receptors12,13. AT1R is also involved 
in cerebral edema and the behavioral impairment observed during PbA infection, and these could be a result of 
Ang II-induced CD8+ T-cell sequestration in the brain via AT1R13. Thus, based on the critical role that CD8+ T 
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cells play in protective or harmful responses in different conditions, it is important to understand how the Ang 
II/AT1R axis regulates the response of these cells. However, most of the previous studies used pharmacological 
tools, and the observed effects may not always be due to a specific receptor blockade. In addition, there is no clear 
evidence regarding the role of AT1R expressed by antigen-specific CD8+ T cells regulating their response against 
pathogens during effector or even memory phases, which requires further exploration.
In the context of malaria, CD8+ T cells play a critical protective role during the liver stage22,23. These cells 
become activated soon after exposure to parasites and their response quickly increases following a narrow 
regulated program24–26. The effector response is detectable 24 h after immunization25, followed by accelerated 
expansion of antigen-specific CD8+ T cells, reaching a peak around 5 days after priming25. On days 6–8 after 
immunization, a sudden contraction occurs, probably due to programmed cell death of up to 80% of activated 
cells, restoring homeostasis25,26. After this fast contraction phase, the antigen-specific CD8+ T-cell population 
stabilizes and starts the formation of memory cells around day 15 after priming24. The development and survival 
of this population depends on different cytokines secreted by CD4+ T cells, such as IL-2, IL-4, IL-7 and IL-15, 
which inhibit apoptosis24,27–30. In addition, these cytokines promote differentiation of sub-populations of memory 
cells, which acquire a definitive phenotype around 20 days after immunization24. Given the large number of other 
molecules produced by antigen-presenting cells (APCs) and CD4+ T cells, such as Ang II, and receptors upreg-
ulated in CD8+ T cells during this response, such as AT1R, the Ang II/AT1R axis could also be important in the 
expansion, differentiation, and functional capacity of effector and memory CD8+ T cells.
In the current study, we evaluated the role of AT1R expressed in antigen-specific CD8+ T cells in their 
expansion, differentiation, and function during the response induced by immunization of mice with attenu-
ated sporozoites of Plasmodium berghei. We used wild-type (WT; AT1R+/+) and AT1R−/− CD8+ T cells from 
ovalbumin (OVA)-specific TCR transgenic mice (OT-I), which allows the response of SIINFEKL-specific CD8+ 
T-cell population to be monitored31–37. For immunization, we used radiation-attenuated sporozoites (γ -spz) of 
Plasmodium berghei CS5M, which express the OVA peptide, SIINFEKL, replacing the natural epitope from the 
circumsporozoite (CS) protein34–37. This system provides a clean experimental set up to evaluate the role of AT1R 
in antigen-specific CD8+ T cells during the effector and memory phases of the response.
Our results revealed that clonal expansion and contraction of AT1R−/− OT-I cells were lower in magnitude 
compared with AT1R+/+ OT-I cells. AT1R−/− cells showed stronger activation and exhaustion profiles along with 
lower polyfunctional capacity compared with AT1R+/+ cells during the effector phase. During the memory devel-
opment phase, antigen-specific AT1R−/− OT-I cells still showed higher expression of activation, central mem-
ory markers but increased polyfunctional capacity, in contrast to AT1R+/+ OT-I control. In addition, lack of 
AT1R expression promotes a larger memory population with lower cytotoxic activity. Genetic ablation of AT1R 
in parasite-specific CD8+ T cells also improves control of the parasite burden and survival of mice during lethal 
disease induced by blood-stage PbA infection. Our study reveals different roles of AT1R in antigen-specific CD8+ 
T cells during the effector and memory phases of the response against Plasmodium.
Results
AT1R is important to the expansion of antigen-specific CD8+ T cells. To determine the importance 
of AT1R in regulating the antigen-specific CD8+ T-cell response, we first evaluated the role of AT1R in the primary 
clonal expansion and homeostatic contraction of antigen-specific CD8+ T cells induced by immunization with 
P. berghei CS5M γ -spz. Naive AT1R+/+ or AT1R−/− OT-I cells (CD45.1+) were adoptively transferred into H-2kb 
C57BL/6 mice (CD45.2+) and 24 h later the recipient mice were immunized with 105 freshly isolated P. berghei 
CS5M γ -spz, which express the H-2kb-restricted peptide SIINFEKL in the CS protein34. On days 3, 7, 12, 20, and 32 
post immunization (p.i.), OT-I cells were isolated from the spleen, and the percentage and absolute number were 
determined (Fig. 1A) based on the the gate strategy showed in the Supplementary Fig. S1.
Figure 1 shows a robust expansion of AT1R+/+ OT-I cells reaching a peak on day 7, and a quick contraction 
was observed thereafter. After day 12, the magnitude of the response is stabilized and remains unchanged up to 
day 20, when decreases occur until day 32 (Fig. 1B,C). AT1R−/− OT-I cells also expand until day 7 followed by 
contraction. However, the number of AT1R−/− OT-I cells at the peak of expansion and at day 12 p.i. is lower than 
the number of AT1R+/+ OT-I cells, indicating the importance of AT1R in the expansion of antigen-specific CD8+ 
T cells during the effector phase (Fig. 1B,C). Moreover, the number of AT1R−/− OT-I cells is still lower at day 20 
p.i. (Fig. 1B,C). In parallel, analysis in non-immunized mice (naive) revealed that, without immunization, the 
non-activated OT-1 cells disappear over time (Supplementary Fig. S2), confirming that stimulation is dependent 
on the presence of the antigen.
It is known that clonal expansion initiates after cell differentiation, and an increase in the total number of 
antigen-specific cells is detected only at 48–72 h after spz immunization25. Thus, to understand the lower expan-
sion of AT1R−/− OT-I cells, we tested if AT1R plays a key role in triggering signals to initiate clonal expansion 
by detecting cellular proliferation at 72 h after immunization. To do so, carboxyfluorescein succinimidyl ester 
(CFSE)-stained naive AT1R+/+ and AT1R−/− OT-I cells (2 × 106 cells; CD45.1+) were adoptively transferred 
into WT mice (CD45.2+). After 24 h, recipient mice were inoculated with irradiated P. berghei CS5M sporozoites 
and 72 h after immunization, OT-I cells were isolated from the spleen and quantified by CFSE dilution using 
flow cytometry (Fig. 2). Early proliferation (up to 72 h) was not affected by AT1R deficiency because the rate of 
CFSE dilution and the number of divided OT-I were the same for AT1R+/+ and AT1R−/− OT-I cells (Fig. 2) in 
γ -spz-immunized mice. In non-immunized mice (naive), OT-I cells do not proliferate.
AT1R upregulates the IL-2/IL2-R axis in antigen-specific CD8+ T cells during the effector phase. 
A possible mechanism to explain the lower expansion of AT1R−/− OT-I cells from 3 days after immunization is the 
alteration in the expression of the IL-2R subunits and/or IL-2 production, because IL-2 signaling is important for 
CD8+ T-cell proliferation as shown in a number of models including γ -spz immunization24,29,30.
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Figure 3 and Supplementary Figure S3 shows that at day 3, the percentage of CD25+ CD8+ T cells and expres-
sion of CD25, determined by median fluorescence intensity (MFI), is slightly but significantly lower in the 
AT1R−/− OT-I cells. From day 3, there is an increase in the percentage of CD25+ AT1R+/+ OT-I cells and CD25 
expression, which reaches a peak at day 12 p.i. (Fig. 3A,B and Supplementary Fig. S3), then CD25 expression 
decreases during memory development phase, in agreement with the literature and our results using recombinant 
vaccinina virus expressing OVA (data not shown) (Fig. 3A,B and Supplementary Fig. S3)30. In AT1R−/− OT-I cells, 
CD25 expression is also upregulated, but to a lesser extent inasmuch the percentage of CD25+ cells and expres-
sion are significantly lower in the AT1R−/− population up to day 12 p.i. (Fig. 3 and Supplementary Fig. S3). With 
regard to the percentage of CD122+ OT-I cells and CD122 expression, a similar profile to CD25 was observed 
(Fig. 3C,D and Supplementary Fig. S3). Functional analysis revealed AT1R−/− OT-I cells produced considerably 
lower amounts of IL-2 at days 7 and 12 p.i. in comparison with AT1R+/+ OT-I cells (Fig. 3E). This is in agreement 
with the lower expression of IL-2R subunits and lower expansion of AT1R−/− OT-I cells from day 3 to day 32. 
These results indicate the importance of AT1R for the expansion of antigen-specific CD8+ T cells during the 
effector phase, which could be correlated to the increased production of IL-2 and upregulation of IL-2R subunits.
AT1R prevents exacerbated activation of antigen-specific CD8+ T cells during the effector and 
memory phases. Next, to verify if AT1R plays a role in the activation of antigen-specific CD8+ T cells 
induced by γ -spz immunization, the expression of different T-cell activation surface markers, such as CD69, 
CD44, CD62L, and CD160, were evaluated at days 7, 12, 20, and 32 p.i.
As depicted in Figs 4 and S3C, from day 3, expression of CD69 upregulates in both AT1R+/+ and AT1R−/− OT-I 
cells. However, CD69 frequency and expression become higher in AT1R−/− OT-I cells than in AT1R+/+ OT-I cells 
from day 12 to day 32 p.i. (Fig. 4A,B and Supplementary Fig. S3C). CD160 expression decreases in AT1R+/+ OT-I 
cells from day 7, whereas the frequency of CD160+ cells and expression in the AT1R−/− OT-I population is higher 
from day 12 (Fig. 4C,D and Supplementary Fig. S3D).
Similarly, the frequency and expression of CD44 are significantly higher in AT1R-deficient cells after 12 days 
p.i. (Fig. 4E,F and Supplementary Fig. S3E). CD62L, known as L-selectin, characterizes effector cells when its 
Figure 1. AT1R is important to the expansion of antigen-specific CD8+ T cells. AT1R+/+ or AT1R−/− OT-I 
cells (CD8+ CD45.1+) recovered from the spleen of immunized recipient mice (CD45.2+) were analyzed 
on days 0, 3, 7, 12, 20, and 32 post immunization. (A) Schematics of the experimental design. 1 × 104 Naive 
AT1R+/+ or AT1R−/− OT-I cells (CD8+CD45.1+) were adoptively transferred to WT C57BL/6 mice (CD45.2+) 
recipients 1 day before intravenous inoculation with 1 × 10λ γ -irradiated P. berghei CS5M sporozoites. Mice 
were euthanized at the indicated time points for recovery and analysis of OT-I cells. (B) Representative 
CD8+CD45.1+(OT-I cells) plots gated on total lymphocytes. Percentages represent the proportion of OT-I cells 
(CD8+CD45.1+) among the total CD8+ T cells per spleen, recovered at days 3, 7, 12, 20, and 32 p.i. The gating 
strategy used for flow cytometry analysis is indicated in the Materials and Methods section. (C) Total number 
of AT1R+/+ (filled circle; continued line) or AT1R−/− (filled square; broken line) OT-I cells per spleen at days 
3 (p = 0.136), 7 (*p = 0.044), 12 (*p = 0.003), 20 (*p = 0.0002), and 32 (p = 0.129) post inoculation, calculated 
as the frequencies obtained by CD8+ CD45.1+ staining, multiplied by the total number of cells obtained 
after spleen excision. Data are means ± SEM of 4 mice per group and are representative of 3 independent 
experiments with similar results for each indicated time point. Abbreviations: AT1R, angiotensin II type 1 
receptor; WT, wild-type.
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Figure 2. AT1R does not affect early proliferation (up to 72 h) of antigen-specific CD8+ T cells. (A) Schematics 
of the experimental design. WT C57BL/6 mice (CD45.2+) received 2 × 106 CFSE-labeled naive AT1R+/+ and 
AT1R−/− OT-I cells (CD8+CD45.1+) 1 day before inoculation with irradiated P. berghei CS5M sporozoites. (B) Mice 
were euthanized 3 days later, and CFSE dilutions on CD8+CD45.1+ T cells (OT-I cells) harvested from the spleen of 
non-imunized (naïve) and γ –spz immunized mice were analyzed by flow cytometry. Histograms represent OT-I cells 
taken from the spleen. (C) Number of divided OT-I cells 3 days after γ -spz inoculation, calculated by the frequency 
of CFSEloCD8+CD45.1+ cells in the spleen multiplied by the total number of cells obtained after spleen excision 
(p = 0.139). Data are means ± SEM of 4 mice per group and are representative of 3 independent experiments with 
similar results for each indicated time point. Abbreviation: CFSE, carboxyfluorescein diacetate succinimidyl ester.
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expression is decreased but also represents central memory cells when its expression is increased after T-cell 
activation38,39. As observed in the Figs 4 and S3F, the frequency and expression of CD62L is significantly lower in 
AT1R−/− OT-I cells during the effector phase of the response (up to day 12 p.i.). However, during memory devel-
opment phase (days 20 and 32), CD62L expression and frequency are higher in AT1R−/− cells than in AT1R+/+ 
cells (Fig. 4G,H and Supplementary Fig. S3F).
The higher expression of CD69, CD44, CD160 and the lower expression of CD62L suggest that AT1R−/− OT-I 
cells are phenotypically more activated than AT1R+/+ cells during the effector phase (up to day 12). The higher 
expression of CD44 and CD62L, during memory phase, also indicates that the AT1R−/− OT-I cells progress to a 
central memory phenotype.
Figure 3. AT1R upregulates IL-2 production and IL-2R expression in antigen-specific CD8+ T cells during 
the effector phase. 1 × 104 naive AT1R+/+ or AT1R−/− CD45.1+ OT-I cells were adoptively transferred to WT 
C57BL/6 (CD45.2+) recipients 1 day before IV inoculation with 1 × 105 γ -irradiated P. berghei CS5M sporozoites. 
IL-2R subunits (CD25 (α -chain) and CD122 (β -chain)) and IL-2 production were evaluated in AT1R+/+ and 
AT1R−/− OT-I cells (CD8+CD45.1+) recovered from the spleen of immunized recipient mice (CD45.2+) at 
indicated time points post immunization. The gating strategy used for flow cytometry analysis is indicated in 
the Materials and Methods section. (A,B) Representative dot plots and percentage of CD25+ OT-I cells among 
total OT-I cells in the spleen on days 3 (*p = 0.0289), 7 (*p = 0.0376), 12 (*p = 0.0292), 20 (p = 0.7879), and 32 
(p = 0.663) post immunization. (C,D) Representative dot plots and percentage of CD122+ OT-I cells among 
total OT-I cells in the spleen on days 7 (*p = 0.0161), 12 (*p = 0.048), 20 (p = 0.2063), and 32 (p = 0.281) post 
immunization. Data are means ± SEM of 4 mice per group and are pooled from 2 independent experiments 
with similar results for each indicated day. (E) IL-2 production in AT1R+/+ and AT1R−/− and OT-I was evaluated 
after 4-h ex vivo re-stimulation with cognate peptide on days 7 (*p = 0.0007), 12 (*p = 0.007), 20 (p = 0.19), 
and 32 (p = 0.9887) post immunization. Data are means ± SEM of 4 mice per group and are pooled from 2 
independent experiments with similar results for each indicated day. Abbreviations: IL-2, interleukin-2; IL-2R, 
interleukin-2 receptor.
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Figure 4. AT1R prevents exacerbated activation of antigen-specific CD8+ T cells during effector and 
memory phases. Percentage of cells expressing the markers of activation, CD69, CD160, CD44, and CD62L, 
were evaluated in AT1R+/+ and AT1R−/− OT-I cells (CD8+CD45.1+) recovered from the spleen of immunized 
recipient mice (CD45.2+) at indicated time points post immunization. The gating strategy used for flow 
cytometry analysis is indicated in the Materials and Methods section. (A,B) Representative dot plots and 
percentage of CD69+ OT-I cells among total OT-I cells in the spleen on days 3 (p = 0.4255), 7 (p = 0.9451), 12 
(*p = 0.0210), 20 (*p = 0.0310), and 32 (*p = 0.0003) post immunization. (C,D) Representative dot plots and 
percentage of CD160+ OT-I cells among total OT-I cells in the spleen on days 7 (p = 0.9054), 12 (*p = 0.0287), 
20 (*p = 0.0095), and 32 (*p = 0.0069) post immunization. Data are means ± SEM of 4 mice per group and  
are pooled from 2 independent experiments with similar results for each indicated day. (E,F) Representative  
dot plots and percentage of CD44+ OT-I cells among total OT-I cells in the spleen on days 7 (p = 0.2), 12  
(p = 0.8425), 20 (*p = 0.0002), and 32 (*p = 0.0296) post immunization. (G,H) Representative dot plots and 
percentage of CD62L+ OT-I cells among total OT-I cells in the spleen on days 7 (*p = 0.0009), 12 (*p = 0.0115), 
20 (*p = 0.0139), and 32 (*p = 0.0052) post immunization. Data are means ± SEM of 4 mice per group and are 
pooled of 3 independent experiments with similar results for each indicated day.
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In γ -spz immunized mice, OT-I cells are only stimulated by parasites expressing the SIINFEKL epitope34,36,37 
but during blood-stage malaria, a low level of non-specific activation has been described33. Thus, to check whether 
non-specific activation could occur, we analyzed the activation status of the endogenous CD8+ T cell population 
(CD8+ CD45.1−). We reasoned that if non-specific activation of OT-I cells takes place, activation of endogenous 
CD8+ T cells in the presence of γ -irradiated P. berghei CS5M sporozoites will also take place. No detectable changes 
in the absolute number, expression of CD25, CD122, activation, exhaustion, or memory markers were observed 
in the total endogenous CD8+ T cells in comparison with non-immunized recipient mice (Supplementary 
Figs S2, S4, and S5). These observations confirm that immunization induces stimulation in the transferred CD8+ 
T cells in an antigen-specific manner.
AT1R decreases exhaustion of antigen-specific CD8+ T cells. So far, our results indicate that AT1R 
expression affects expansion and activation phenotypes during γ -spz-induced antigen-specific CD8+ T-cell 
response. It is known that on activation, and with progressive differentiation to effector cells, the so-called inhib-
itory receptors or cellular exhaustion markers are expressed, which function as a negative feedback mechanism 
and are linked to activation and effector differentiation40,41. Thus, to evaluate the possible influence of AT1R in 
exhaustion, we characterized the frequency and expression of exhaustion markers, such as PD1, CTLA4, and 
LAG3.
Figure 5 and Supplementary S6A shows that PD1 expression is higher in AT1R−/− cells than in AT1R+/+ cells 
at day 12 p.i. (effector phase) and day 32 p.i. (memory phase). The frequency of LAG3+ cells and expression in 
AT1R+/+ OT-I cells decrease after 7 days p.i., whereas in AT1R−/− OT-I cells they remain significantly higher from 
day 12 (Fig. 5C,D and Supplementary Fig. S6B). CTLA4 expression and frequency upregulate in AT1R−/− OT-I 
cells at day 32 (Fig. 5E,F and Supplementary Fig. S6C).
The higher expression of such markers in AT1R−/− antigen-specific CD8+ T cells is in agreement with the 
observations described above, supporting the idea of higher activation along with exhaustion of AT1R-deficient 
CD8+ T cells, mainly 12 days p.i.
AT1R inhibits the upregulation of IL7-Rα expression in antigen-specific CD8+ T cells during the 
memory development phase. Next, we evaluated the expression levels of markers of short-term effector 
cells and memory cells, KLRG1 and IL-7Rα (CD127), respectively28,30,38,39. Figures 6 and S4 shows that during 
effector response (days 7 and 12), the frequency and expression of KLRG1 and IL-7Rα are similar in both AT1R+/+ 
and AT1R−/− OT-I cells. As also described previously in another system38, from day 12 KLRG1 expression and 
frequency start to decrease, whereas IL-7Rα expression is increased, which suggests the appearance of terminally 
differentiated antigen-specific memory cells (Fig. 6 and Supplementary Fig. S6). However, IL-7Rα expression and 
frequency are significantly higher in AT1R−/− OT-I cells (Fig. 6 and Supplementary Fig. S6E). Together with CD44 
and CD62L expression, this result suggests that after the contraction, more surviving AT1R−/− antigen-specific 
CD8+ T cells transition to a central memory phenotype.
AT1R fosters polyfunctional CD8+ T cells during the effector phase and cytotoxic CD8+ T cells 
during the memory phase. Because AT1R seems to be important to prevent exacerbated activation and 
decrease exhaustion, we evaluated the role of AT1R in the functional capacity of antigen-specific CD8+ T cells. 
Functional populations of cells with cytotoxic capacity, measured by the surface mobilization of CD107a, as 
well as producing cytokines (IFN-γ , TNF-α , and IL-2), were determined after ex vivo restimulation with 
SIINFEKL-pulsed target cells (Supplementary Fig. S7)29,42,43.
Boolean gates combinatory analysis at days 7, the peak of the effector WT and AT1R−/− OT-I responses, and 12 
p.i. revealed a significant percentage of AT1R+/+ OT-I cells differentiated into polyfunctional effector cells, capable 
of simultaneously producing 2 or more cytokines and/or with cytotoxic capacity (represented by CD107a expres-
sion on the cell surface) (Fig. 7). This functional capacity decreases over time (memory development phase), and 
a higher percentage of memory cells with monofunctional phenotype, mainly cytotoxic (CD107a+), become 
evident (Fig. 8). Meanwhile, there is a lower frequency of AT1R−/− OT-I cells with polyfunctional capacity, mainly 
showing 4 (CD107a+ IFN-γ + TNF-α + IL-2+) or 3 (CD107a+ IFN-γ + IL-2+ ) functions during the effector phase, 
as observed at days 7 and 12 p.i. (Fig. 7). Moreover, a lower percentage of monofunctional AT1R−/− OT-I cells cells 
producing only IFN-γ or IL-2 was also observed, in agree with the results described above (Fig. 7).
During the memory phase (at days 20 and 32), there is an increase in the percentage of AT1R−/− OT-I cells 
with polyfunctional capacity (Fig. 8). In addition, there is a decrease in memory AT1R−/− OT-I cells showing 
only cytotoxic function (CD107a expression only) in comparison with AT1R+/+ OT-I cells at day 32 (Fig. 8). 
Interestingly, in the liver, a significantly higher number of AT1R–/– OT-I cells was observed at 20 and 32 days after 
immunization (Fig. 9). However, a lower percentage of AT1R−/− OT-I cells producing CD107a, alone or in combi-
nation, in comparison with AT1R+/+ OT-I cells was verified at day 32 p.i. (Fig. 9). These results demonstrate that 
AT1R is important to the generation of antigen-specific CD8+ T cells with cytotoxic function during the memory 
phase.
Lack of AT1R expression in parasite-specific CD8+ T cells ameliorates protection against lethal 
disease induced by P. berghei ANKA infection in mice. So far our results show that AT1R plays a piv-
otal role in the antigen-specific CD8+ T cell response, influencing the expansion, contraction, and expression of 
IL-2R, IL-7R, and other surface markers. Previously, we showed that pharmacological inhibition of AT1R protects 
mice against cerebral malaria (CM) during blood-stage malaria13. Then, to verify the biological significance of 
the altered CD8+ T cell function due to lack of AT1R, we examined the lethal disease induced by P. berghei ANKA 
(PbA) infection13,32,33,44,45. Parasitemia and survival curves of mice that received WT or AT1R−/− OT-I cells were 
evaluated after infection with PbA-expressing OVA (OVA-PbA)33 (Fig. 10A). Similar to AT1R−/− cells at days 7 
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and 12 (effector phase) in γ -spz immunized mice (Figs 1 and 7), the expansion of AT1R−/− OT-I cells is lower 
and they are less polyfunctional at day 6 p.i. in OVA-PbA-infected mice (Fig. 10B,C). Interestingly, parasitemia 
at day 6, when CM signs appear13,32,33,44,45, was 32% lower in the infected mice that received AT1R−/− OT-I cells 
(AT1R−/− → WT) (Fig. 10D). This suggests that OT-I cells lacking AT1R have a higher capacity to limit the para-
site burden.
It is well known that C57BL/6 mice infected with PbA die because of CM between 6 and 8 days p.i., whereas 
infected mice dying after that are affected by hyperparasitemia and severe anemia44,45. We characterized CM 
by observing several clinical signs in infected mice, such as hemi- or paraplegia, ataxia, deviation of the head, 
convulsions, and coma between 5 and 8 days p.i.; deaths were checked daily. Importantly, analysis of survival 
curves revealed that 100% of OVA-PbA-infected mice injected with WT OT-I cells (WT → WT) exhibited CM 
signs within 5–7 days p.i. and rapidly died of fatal CM (Fig. 10E). Most (80%) died on day 6 p.i., and all animals 
from this group were dead by day 7 p.i. (Fig. 10E). In contrast, in the infected mice injected with AT1R−/− OT-I 
cells (AT1R−/− → WT), neurological signs of CM began to appear later and the mortality rate increased slowly 
Figure 5. AT1R decreases exhaustion in antigen-specific CD8+ T cells. Percentage of cells expressing 
exhaustion markers, PD-1, LAG-3, and CTLA-4, were evaluated in AT1R+/+ and AT1R−/− OT-I cells 
(CD8+CD45.1+) isolated from the spleen of immunized recipient mice (CD45.2+) at indicated time points post 
immunization. The gating strategy used for flow cytometry analysis is indicated in the Materials and Methods 
section. (A,B) Representative dot plots and percentage of PD-1+ OT-I cells among total OT-I cells in the spleen 
on days 7 (p = 0.9), 12 (*p = 0.0192), 20 (p = 0.9), and 32 (*p = 0.0285) post immunization. (C,D) Representative 
dot plots and percentage of LAG-3+ OT-I cells among total OT-I cells in the spleen on days 7 (p = 0.11), 12 
(*p = 0.0024), 20 (*p = 0.0468), and 32 (*p = 0.0074) post immunization. (E,F) Representative dot plots and 
percentage of CTLA-4+ OT-I cells among total OT-I cells in the spleen on days 7 (p = 0.6), 12 (p = 0.6907), 
20 (p = 0.551), and 32 (*p = 0.0197) post immunization. Data are means ± SEM of 4 mice per group and are 
representative of 2 independent experiments with similar results for each indicated time point. Abbreviations: 
CTLA-4, cytotoxic T-lymphocyte-associated protein 4; LAG-3, lymphocyte-activation gene 3; PD-1, programmed 
cell death 1.
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throughout days 6–8. These mice showed a significant amelioration of survival; 40% and 25% of mice survived 
at days 6 and 7, respectively (Fig. 10E). In the mice that did not develop CM, the mortality rate increased until 
day 26 and mice died as a result of hyperparasitemia (up to 70%). In agreement with our previous study13, these 
results highlight that altered functions of parasite-specific CD8+ T cells due to ablation of AT1R expression ame-
liorates protection of mice against the lethal disease induced by PbA infection.
Discussion
In this work, we used a model of immunized mice with irradiated Plasmodium sporozoites to evaluate the role of 
AT1R in the regulation of the antigen-specific CD8+ T-cell response. Although Ang II binds 2 different receptors, 
AT1R and AT2R, previous studies have shown that AT1R expression is upregulated in T cells in vitro and 
during Plasmodium berghei ANKA (PbA) infection and mediates most of the effects of Ang II in T cells5–15,18,20,21. 
The upregulated AT1R plays a role in activation, effector function, CD8+ T-cell sequestration in the brain, cer-
ebral edema, and behavioral impairment during the blood stage of PbA infection, as well as in other models of 
diseases10,11,13,15,18–21. However, the specific role of AT1R expressed by antigen-specific CD8+ T cells in regulating 
their response is not yet clear yet. To our knowledge, this is the first study highlighting the influence of this receptor 
in the course of the antigen-specific CD8+ T-cell response.
Many studies have taken advantage of the use of different transgenic lineages of Plasmodium32–34. For instance, 
P. berghei CS5M is a P. berghei strain in which the native H-2Kd–restricted epitope SYPSAEKI from the C-terminus 
of the CS protein is substituted with the H-2Kb–restricted epitope SIINFEKL34. In this parasite lineage, the 
SIINFEKL is presented as a natural CS epitope, including a stage-specific pattern of expression, antigen pres-
entation, and processing34. In addition, only in C57BL/6 mice immunized with P. berghei CS5M parasites there 
is a robust SIINFEKL-specific immune response, differently in the mice immunized with the parental lineage 
P. berghei ANKA34. Moreover, upregulation of CD69 and the production of IFN-γ by OT-I cells occurs only in 
recipient mice injected with P. berghei CS5M sporozoites36. Here we also observed CD69 upregulation, as well as 
other markers of activation, only in the cells that respond to the SIINFEKL epitope. The P. berghei CS5M sporo-
zoites are not able to induce activation of endogenous CD8+ T-cell clones specific to other antigens. Recently, it 
was demonstrated that effector antigen-specific CD8+ T cells activity is restricted to the immediate microenviron-
ment of the infected cell following interactions with the cognate antigen and bystander killing of parasites was not 
Figure 6. AT1R inhibits the upregulation of IL7-Rα expression in antigen-specific CD8+ T cells during the 
memory development phase. Percentage of cells expressing IL-7Rα and KLRG-1 were evaluated in AT1R+/+ 
and AT1R−/− OT-I cells (CD8+CD45.1+) harvested from the spleen of immunized recipient mice (CD45.2+) and 
analyzed at the indicated time points post immunization. The gating strategy used for flow cytometry analysis 
is indicated in the Material and Methods section. (A,B) Representative dot plots and percentage of KLRG1+ 
OT-I cells among total OT-I cells in the spleen on days 7 (p = 0.5902), 12 (p = 0.07), 20 (p = 0.2654), and 32 
(p = 0.8903) post immunization. (C,D) Representative dot plots and percentage of IL-7Rα + OT-I cells among 
total OT-I cells in the spleen on days 7 (p = 0.4388), 12 (p = 0.2857), 20 (*p = 0.0089), and 32 (*p = 0.0429) post 
immunization. Data are means ± SEM of 4 mice per group and are representative of 2 independent experiments 
with similar results for each indicated day. Abbreviations: IL7-Rα , interleukin-7 receptor α -chain; KLRG-1, 
killer cell lectin like receptor G1.
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observed37. Together, these observations explicitly demonstrate that, during γ -spz immunization, antigen-specific 
CD8+ T cells are stimulated and respond only to the cognate antigen in an antigen specific-manner.
It is known that the CD8+ T-cell response initiates by antigen recognition by naive cells, upregulation of acti-
vation molecules, and clonal expansion, followed by acquisition of effector functions22,24,25. In this work, a peak in 
the number of OT-I cells in the spleen was observed at 7 days p.i., which suddenly decreased due to homeostatic 
contraction, in accordance with previous studies using this model and in other types of infections25,26,39,46,47. In 
addition, our observations suggest that during the effector phase, AT1R−/− CD8+ T cells have a lower rate of prolif-
eration but also contract to lesser extension. Since IL-2 signaling is important for CD8+ T-cell proliferation24,29–32, 
a possible molecular mechanism is that AT1R upregulates IL-2R and stimulates IL-2 production by CD8+ T 
cells during the effector phase. In agree, previous studies demonstrated that Ang II/AT1R axis promotes T-cell 
proliferation by increasing IL-2 production, via induction of NADPH oxidase-mediated ROS generation and/or 
activation of calcineurin phosphatase5–7,10. After reaching a peak of expansion, the CSP-specific CD8+ T cells 
reduce extensively due to massive apoptosis, becoming a stable memory population capable of mediating pro-
tection against a posterior sporozoite challenge24–26,38,39. Our data suggest that AT1R accelerates contraction of 
the responding population, which is confirmed by the higher inclination in the curve after the peak of clonal 
expansion at day 7. A possible mechanism is the lower expression of IL-7R in the AT1R+/+ cells during the con-
traction phase, because IL-7 plays an overlapping and complimentary role with IL-2 in the survival of memory 
cell precursors during memory cell development28,30,48–50. Given that AT1R-deficient cells, expressing higher levels 
of IL-7R, survive to generate a similar level of memory as AT1R-sufficient cells at day 32 pi in the spleen. In the 
liver, effector cells lacking AT1R may also have an intrinsic survival advantage because they generate a higher 
number of memory cells. This advantage is particularly critical for memory cells in the liver, where there may be 
a shortage of the cytokine or chemokine interactions required to sustain the formation of memory cells35. Future 
experiments will address the exact molecular mechanisms involved in this phenomenon.
AT1R−/− OT-I cells also significantly express higher levels of CD69 and CD160, and less of CD62L during 
effector phase, which indicates that AT1R decreases the exacerbated activation of antigen-specific CD8+ T cells. 
During the memory development phase (days 20 and 32), CD62L and IL-7Rα expression were higher in AT1R−/− 
OT-I cells, which indicate a faster transition of AT1R−/− antigen-specific CD8+ T cells to a central memory 
phenotype28,30,38,39,48–50. The higher expression of CD69 and CD44 in memory AT1R−/− OT-I cells suggest that 
these cells are continuing to respond to antigen, which could contribute to their exhausted phenotype. Another 
possible impact is the increase of IL-2 production by memory AT1R−/− OT-I cells. CD69 signaling through NFAT 
and AP-1 transcription factors upregulates IL-2 expression51.
Figure 7. AT1R expression in effector antigen-specific CD8+ T cells fosters polyfunctional capacity. 1 × 104 
naive AT1R+/+ or AT1R−/− CD45.1+ OT-I cells were adoptively transferred to WT C57BL/6 (CD45.2+) recipients 
1 day before intravenous inoculation with 1 × 105 γ -irradiated P. berghei CS5M sporozoites. (A,B) Seven (A) or 
12 days (B) post immunization, spleen suspensions were stimulated ex vivo with SIINFEKL peptide-coated 
target cells. CD8+ T-cell functionality was determined by the combinatorial analysis of the functional subsets 
of responding CD8+CD45.1+ T cells residing in the spleen. Responding cells are defined by the capacity to 
produce at least 1 of the 3 cytokines and/or surface mobilization of CD107a after ex vivo stimulation. The bar 
charts indicate the frequency of CD8+CD45.1+ T lymphocytes (OT-I cells) expressing each of the 15 possible 
combinations of CD107a, IFN-γ , TNF-α , and IL- 2 among responding OT-I cells at (A) day 7 and (B) day 12 
post immunization. Bars represent means ± SD of 5 or 6 mice per group and are representative of 2 independent 
experiments with similar results for each indicated time point.
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Besides higher activation, we observed a higher percentage of AT1R-deficient OT-I cells expressing the 
exhaustion molecules PD-1, CTLA-4, and LAG-3. Typically, exhausted T cells lose their polyfuncitonality, the 
ability to simultaneously produce cytokines such as IL-2, IFN-γ , TNF-α and to degranulate52. This correlates with 
the lower polyfunctional capacity of AT1R−/−OT-I cells during the effector phase. Moreover, exhausted CD8+ 
T cells are eventually deleted, which could also explain why AT1R−/− cells are present at lower numbers during 
the effector phase. During memory phase, even though AT1R−/− cells are more exaushted, their polyfunctional 
capacity increases. However, accordingly with the progressive loss of effector functions, the ability to produce IL-2 
is lost followed by the ability to produce TNF-α , and then IFN-γ 52, the percentages of AT1R−/− OT-I cells able to 
produce all cytokines but IL-2 and/or TNF-α are higher when compared to WT cells (Fig. 8).
Here, it was also observed that AT1R–/– OT-I cells form a 2.5 larger memory cell population in the liver. This 
can deliver important information in this model. Parasite elimination is dependent on each and every para-
site being found and eliminated by at least one cognate CD8+ T cell37. In addition, because there are redun-
dant effector mechanisms for parasite elimination (such as IFN-γ and TNF-α secretion), the total number of 
antigen-specific CD8+ T cells is a critical factor in determining the ability of CD8+ T cells to control liver-stage 
malaria parasites29,37,53–57. Here, we observed that there were no distinguishable differences in the capacity to 
produce cytokines between memory WT and AT1R–/– OT-I cells in the liver (Supplementary Fig. S7). Although 
liver-residing AT1R–/– OT-I cells are less committed to cytotoxic function, as shown by the polyfunctional anal-
ysis, there is not much difference in the overall functionality in comparison with the WT control (Fig. 9). Thus, 
the number of memory cells becomes an important factor to limit parasite development in the liver29,37,56,57. 
Collectively, these data suggest that it is plausible that AT1R–/– memory cells could confer better protection 
from challenges with live sporozoites. Here we verified that genetic ablation of AT1R expression, specifically 
in parasite-specific CD8+ T cells, delays CM-specific neurological signs and confers better protection against 
PbA-induced lethal disease in mice. In addition, although expansion and the polyfunctional capacity of effector 
AT1R−/− OT-I cells are also lower during the blood stage, they showed a better capacity to limit parasitemia when 
CM signs appeared (day 6 p.i.). This is in agreement with evidence showing that higher numbers of CD8+ T cells 
and production of IFN-γ drive the rapid increase in parasite biomass from day 6 p.i., when mice develop ECM58,59. 
Moreover, these effects have an important biological significance, because an adjuvant treatment that delays mor-
tality is clinically relevant for human malaria, since most patients with CM die before the beneficial effects of 
conventional anti-malarial treatment are observed60. Thus, these data corroborate that modulation of the Ang II/
AT1R axis could be an interesting target in an adjunctive therapy to improve poor malaria outcomes13,61.
Together, our results indicate that AT1R plays a pivotal role in the antigen-specific CD8+ T cell response, influ-
encing the proliferation and expression of IL-2R, IL-7R, and other surface markers. Our group and others have 
Figure 8. AT1R promotes cytotoxic antigen-specific CD8+ T cells during the memory phase. 1 × 104 naive 
AT1R+/+ or AT1R−/− CD45.1+ OT-I cells were adoptively transferred to WT C57BL/6 (CD45.2+) recipients 1 
day before intravenous inoculation with 1 × 105 γ -irradiated P. berghei CS5M sporozoites. (A,B) Twenty (A) or 
32 days (B) post immunization, spleen suspensions were stimulated ex vivo with SIINFEKL peptide-coated 
target cells. CD8+ T-cell functionality was determined by the combinatorial analysis of the functional subsets 
of responding CD8+CD45.1+ T cells residing in the spleen. Responding cells are defined by the capacity to 
produce at least 1 of the 3 cytokines and/or surface mobilization of CD107a after ex vivo stimulation. The bar 
charts indicate the frequency of CD8+CD45.1+ T lymphocytes (OT-I cells) expressing each of the 15 possible 
combinations of CD107a, IFN-γ , TNF-α , and IL- 2 among responding OT-I cells at days (A) 20 and (B) 32 post 
immunization. Bars represent mean ± SD of 5 or 6 mice per group and are representative of 3 independent 
experiments with similar results for each indicated time point.
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shown that Ang II plays a pivotal role in regulating the T cell response in an autocrine or paracrine manner via 
AT1R, which is upregulated in activated T cells10–15,21. In addition, other studies show that different innate immune 
cells, such as monocytes, macrophages, and dendritic cells, produce Ang II and express higher levels of mRNA 
of the different renin-angiotensin system (RAS) components than T cells8,10,16–20. During the encounter with the 
antigen, in the context of co-stimulatory stimuli, Ang II activates AT1R in T cells initiating distinct transcrip-
tional profiles that regulate avidity by antigen, activation, clonal expansion, migration and effector function10–21. 
Moreover, because the events that control the initial activation of T cells ultimately determine the fate of the respond-
ing cell30,48, contraction of the effector population and memory development could also be affected by Ang II-induced 
AT1R activation. However, the AT1R-induced signaling pathways behind these processes remain undefined. It is 
known that AT1R activates multiple downstream signals, including PKC, MAPKs (ERK1/2, P38 MAPK, JNK), PI3K/
PKB/mTOR, tyrosine kinases (Pyk2, c-Src family kinases, Tyk2, FAK), NFκ B, Src-JAK/STAT, and NADPH oxidase, a 
major source of reactive oxygen species (ROS)62. Many of these pathways are important to induce pro-inflammatory 
transcription factors, T cell activation, proliferation, chemotaxis, cytokine production, and to regulate the develop-
ment of memory CD8+ T cells39,49,62–64. Thus, the diversity of the signaling pathways induced by AT1R could explain 
the pivotal role of this receptor in different aspects of T cell response. Thus, blockade of AT1R in antigen-specific 
CD8+ T cells could affect a variety of downstream functions and other regulatory signals that shape the kinetics of 
the T cell response30, making AT1R-deficient OT-I cells differ from WT OT-1 cells in many aspects. Future experi-
ments will address the role of the Ang II/AT1R axis in the function of other immune cells involved in the regulation 
of the CD8+ T-cell response, such as dendritic cells, CD4+ T cells, and NK cells, to better understand these different 
Figure 9. AT1R induces cytotoxic memory antigen-specific CD8+ T cells in the liver. 1 × 104 naive AT1R+/+ 
or AT1R−/− CD45.1+ OT-I cells were adoptively transferred to WT C57BL/6 (CD45.2+) recipients 1 day before 
intravenous inoculation with 1 × 105 γ -irradiated P. berghei CS5M sporozoites. (A) Total number of AT1R+/+ or 
AT1R−/− OT-I cells per liver at days 20 (*p = 0.0073) and 32 (*p = 0.0013) post inoculation, calculated as the 
frequencies obtained by CD8+CD45.1+ staining, multiplied by the total number of cells obtained after liver 
excision. Data are means ± SEM of 4 mice per group and are representative of 2 independent experiments 
with similar results for each indicated time point. (B,C) Twenty (B) or 32 (C) days post immunization, T cells 
were recovered from the liver and were stimulated ex vivo with SIINFEKL peptide-coated target cells. CD8+ 
T-cell functionality was determined by the combinatorial analysis of the functional subsets of responding 
CD8+CD45.1+ T cells residing in the liver. Responding cells are defined by the capacity to produce at least 1 
of the 3 cytokines and/or surface mobilization of CD107a after ex vivo stimulation. The bar charts indicate the 
frequency of CD8+CD45.1+ T lymphocytes (OT-I cells) expressing each of the 15 possible combinations of 
CD107a, IFN-γ , TNF-α , and IL- 2 among responding OT-I cells at days (B) 20 and (C) 32 post immunization. 
Bars represent means ± SD of 4 mice per group and are representative of 2 independent experiments with 
similar results for each indicated time point.
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Figure 10. Lack of AT1R expression in parasite-specific CD8+ T cells protects mice from lethal disease 
induced by blood-stage PbA infection. 1 × 104 naive WT or AT1R−/− CD45.1+ OT-I cells were adoptively 
transferred to WT C57BL/6 (CD45.2+) recipients 1 day before infection with 5 × 106 RBCs infected with 
OVA-PbA. (A) Schematics of the experimental design. 1 × 104 Naive WT (AT1R+/+) or AT1R−/− OT-I 
cells (CD8+CD45.1+) were adoptively transferred to WT C57BL/6 mice (CD45.2+) recipients 1 day before 
intraperitoneal injection of 5 × 106 infected red blood cells (RBCs) with P. berghei ANKA expressing ovalbumin 
(OVA-PbA). Mice were euthanized at the indicated time point for recovery and analysis of OT-I cells. (B) Total 
number of WT or AT1R−/− OT-I cells per spleen at day 6 post infection, calculated as the frequencies obtained 
by CD8+CD45.1+ staining, multiplied by the total number of cells obtained after spleen excision. Data are 
means ± SEM of 5 mice per group and are representative of 3 independent experiments with similar results 
(*p < 0.0001 in relation to naïve WT OT-I cells; &p < 0.0001 in relation to naïve AT1R−/− OT-I cells #p < 0.0001 
in relation to WT OT-I cells). (C) CD8+ T cell functionality was determined by the combinatorial analysis of 
the functional subsets of responding CD8+CD45.1+ T cells residing in the spleen. Responding cells are defined 
by the capacity to produce at least one of the three cytokines and/or surface mobilization of CD107a after ex vivo 
stimulation. The bar charts indicate the frequency of CD8+CD45.1+ T lymphocytes (OT-I cells) expressing 
each of the 15 possible combinations of CD107a, IFN-γ , TNF-α , and IL-2 among responding OT-I cells. Bars 
represent means ± SD of five mice per group and are representative of three independent experiments with 
similar results. (D) Parasitemia was determined by Giemsa-stained blood smears in infected mice that received 
WT (WT → WT) or AT1R−/− OT-I cells (AT1R−/− → WT). Data are means ± SEM of five mice per group and are 
representative of three independent experiments with similar results (*p = 0.03). (E) Mortality was checked daily 
in the mice infected with OVA-PbA that received WT (WT→ WT; dotted line) or AT1R−/− (AT1R−/− → WT; 
filled line) OT-I cells. The shaded area indicates the time when mice displayed ECM symptoms. After this time, 
mice died with hyperparasitemia. Data are are representative of 3 independent experiments with similar results 
with 10 mice per group (*p = 0.0365).
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immune modulatory effects of AT1R. These studies could be useful in the development of therapeutic strategies 
aimed at improving the protective memory CD8+ T cells or to inhibit harmful effector CD8+ T-cell responses.
Material and Methods
Mice. Six- to eight-week-old male C57BL/6 mice were used in all experiments. Wild-type (WT) C57BL/6 
mice (background CD45.2) were purchased from NCI. OT-I transgenic C57BL/6 mice (background CD45.1) 
that recognize SIINFEKL (peptide at position 257–264 of chicken ovalbumin OVA) presented by H-2Kb were a 
gift from Dr. David Sacks (National Institute of Allergy and Infectious Disease, Bethesda, MD). AT1R−/− mice 
(B6.129P2-Agtr1atm1Unc/J; backcrossed to C57BL/6 at least seven generations; background CD45.2) were pur-
chased from Jackson Laboratories. All mice were housed, bred, and maintained in the animal care facility at Johns 
Hopkins University. All animal procedures were approved by the Institutional Animal Care and Use Committee 
(IACUC) of Johns Hopkins University following the National Institutes of Health (NIH) guidelines for animal 
housing and care.
Mice genotyping and phenotyping. Mice that had been previously backcrossed to the CD45.1 
C57BL/6 background for more than ten generations were used from our colony, as previously described35,64. 
C57BL/6-Agtr1atm1Unc (CD45.1) were crossed to OT-I transgenic C57BL/6 mice (CD45.1) from our colony 
and F1 progeny positive for the TCR transgene were crossed back to C57BL/6-Agtr1atm1Unc mice (CD45.1) to 
obtain TCR transgenic mice homozygous for the Agtr1atm1Unc targeted mutation. To phenotype the mice car-
rying transgenic TCR (OT-I), a drop of blood was collected from the tail vein and verified by flow cytome-
try using anti-mouse Vα 2-fluorescein isothiocyanates (FITC), anti-mouse CD45.1-PE, and anti-mouse 
CD8-APC antibodies (Supplementary Fig. S1A). For genotyping, genomic DNA was extracted from tail clip-
pings using REDExtract-N-Amp tissue PCR kits (Sigma) following the manufacturer’s protocol. Primer infor-
mation and PCR conditions were obtained from the website of Jackson Laboratory (http://jax.org). For PCR, 
primer sequences were: WT locus (oIMR0738), TGAGAACACCAATATCACTG; common (oIMR0739), 
TTCGTAGACAGGCTTGAG; and mutant locus (oIMR6218), CCTTCTATCGCCTTCTTGACG. The PCR 
yielded products of 520 bp if mutant, 483 bp if WT or both sizes if heterozygote. PCR was performed with the 
following cycle settings: 94 °C for 3 min; 94 °C for 30 s; 55 °C for 30 s for annealing, and 72 °C for 1 min for elon-
gation (total of 40 cycles).
Purification of antigen-specific CD8+ T cells and adoptive transfer. Single-cell suspensions from 
spleens of AT1R+/+ OT-I and AT1R−/− OT-I mice were obtained by grinding the spleen between the ground 
ends of 2 microscope slides and then filtering through 100-μ m pore size nylon mesh. CD8+ T cells were puri-
fied by negative selection using magnetic beads following the manufacturer’s protocol (CD8a+ T-cell isolation 
kit; Miltenyi Biotech). Isolated cells were stained with APC-conjugated anti-CD8, FITC-conjugated Vα 2, and 
PE-conjugated CD45.1, and the purity was evaluated by FACS analysis. We obtained approximately 90% of CD8+ 
Vα 2+ CD45.1+ T-lymphocyte (OT-I cells) enrichment (Supplementary Fig. S1B). Adoptive transfer was per-
formed by intravenous injection of 1 × 104 naive AT1R+/+ or AT1R−/− OT-I cells (CD45.1+) into recipient WT 
C57BL/6 mice (CD45.2+) 1 day before sporozoite inoculation (Fig. 1A).
Parasites and immunization. P. berghei CS5M parasite (carrying the H2-Kb SIINFEKL epitope) was gen-
erated as previously described36. P. berghei CS5M spz were harvested from the salivary glands of infected female 
Anopheles stephensi mosquitoes and were radiation attenuated in a cesium radiator at 20,000 rad. Mice that 
received naive AT1R+/+ or AT1R−/− OT-I cells were immunized with intravenous injection of 1 × 105 γ -spz, as 
previously described21,36,37. Mice were euthanized 3 days p.i. to evaluate early cellular proliferation and related 
mechanisms, and at days 7, 12, 20, and 32 to evaluate expansion/contraction, differentiation, and function of 
antigen-specific CD8+ cells during the effector (days 7 and 12) and memory phases (days 20 and 32) (Fig. 1A).
The transgenic Plasmodium berghei ANKA (OVA-PbA) with truncated C-terminal fragment of OVA (amino 
acids 150–386) fused to the N-terminal sequence (amino acids 1–5) of the PbA heat shock protein (hsp) 70 
gene was also used33. A cryopreserved sample of transgenic Plasmodium berghei ANKA-infected red blood cells 
(RBCs) was kindly provided by Dr. Katsuyuki Yui, Nagasaki University, Nagasaki, Japan. The sample was thawed 
and inoculated intraperitoneally into a naive C57BL/6 mouse. Cells were maintained in mice up to seven passages 
before use. Mice that received naive AT1R+/+ or AT1R−/− OT-I cells were infected with OVA-PbA by intraperito-
neal injection of 5 × 106 infected RBCs. The condition of the mice was checked daily. Parasitemia was monitored 
by microscopic examination of standard blood films at day 6 p.i., at the onset of signs of CM13,32,33.
Lymphocyte isolation. The spleens were harvested on days 3–32 and the liver on days 20 and 32 after 
immunization as indicated. Single-cell suspensions of lymphocytes from these organs were obtained by grinding 
the tissues between the ground ends of 2 microscope slides and then filtering them through 100-μ m pore size 
nylon mesh. Numbers of OT-I cells were estimated by automated cell counting using the Trypan blue dye exclu-
sion method (viability was found to be higher than 95%) and flow cytometry with anti-CD45.1 and anti-CD8 
antibodies.
Livers were first perfused with 10 ml of ice-cold Hank’s balanced salt solution through the hepatic portal 
system. To isolate intrahepatic lymphocytes, the liver pellet was resuspended in a 35% Percoll gradient (GE 
Healthcare), followed by centrifugation at 500 × g for 20 min at room temperature. Peripheral blood mononu-
clear cells were purified through a density gradient (Lymphocyte Separation Medium; Mediatech) at 1250 × g 
for 20 min at room temperature without braking. All lymphocytes were prepared and resuspended in DMEM 
supplemented with 10% heat-inactivated fetal bovine serum (FBS), 50 mM sodium bicarbonate, 2 mM glutamine, 
100 U/ml penicillin, 100 μ g/ml streptomycin, 25 mM HEPES.
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Quantification of CD8+ T-cell expansion in vivo. For evaluation of cellular expansion, expansion of 
OT-1 cells was measured by flow cytometry and cell count on days 3, 7, 12, 20, and 32 p.i. In other experiments, 
freshly isolated AT1R+/+ or AT1R−/− OT-I cells were labeled with 1 μ M CFSE (Invitrogen) transferred intrave-
nously to recipient C57BL/6 mice, which were immunized with P. berghei CS5M γ -spz 24 h later. OT-I cells were 
harvested from the spleen of recipient mice 72 h after immunization, and CFSE dilution was evaluated by flow 
cytometry (Fig. 2A).
Antibodies and flow cytometry. All fluorochrome-conjugated monoclonal anti-mouse antibodies were 
purchased from eBioscience or BD unless stated otherwise: CD45.1 (clone A20); PE-Cy7-conjugated CD8 (clone 
53–6.7), CD25 (clone PC61.5), CD122 (clone 5H4) CD69 (H1.2F3), CD160 (clone CNX46–3), CD44 (clone IM7), 
CD62L (clone MEL-14), KLRG1 (clone 2F1), IL-7Rα (clone A7R34), PD-1 (clone J43), LAG-3 (clone C9B7W), 
CTLA-4 (clone UC10–4B9), IFN-γ (clone XMG1.2), IL-2 (clone JES6–5H4), TNF-α (clone MP6-XT22), and 
CD107a (clone 1D4B). PerCP/PE/FITC-conjugated IgG1 and IgG2 isotype controls were all purchased from 
BD Pharmingen. All results were collected with CellQuest software on a FACSCalibur (Becton Dickinson), and 
multi-cytokine experiments were performed on a LSRII flow cytometer (Becton Dickinson).
For flow cytometry, isolated AT1R+/+ or AT1R−/− OT-I cells from recipient C57BL/6 mice were incubated with Fc 
block (anti-mouse CD16 and CD32 antibodies) to block non-specific binding sites for 30 min at 4 °C. Later, the cells 
were washed and incubated with the appropriate concentration of antibodies cited above. IgG isotypes were used 
as irrelevant antibodies to define positive populations as indicated in the gate strategy (Supplementary Fig. S1B). 
At least 105 cells per sample were acquired. Analysis of surface cell markers and intracellular cytokines was per-
formed using FlowJo software (TreeStar). All data were collected and presented in a log scale of fluorescence 
intensity and presented as plots. The percentage of OT-I cells was determined in a gate of CD8+ CD45.1+ cells 
and each analysis was made in relation to the total OT-I cells (gated on CD8+ CD45.1+ cells). as showed in the 
gate strategy (Supplementary Fig. S1C). The MFI data were determined by calculating the median fluorescence 
intensity in the total OT-I cells (gated on CD8+ CD45.1+ cells) considering the fluorescence of the isotype control, 
using FlowJo software (TreeStar) (Supplementary Fig. S1C).
Ex vivo stimulation and intracellular staining. El4 cells (T-cell lymphoma cell line of C57BL/6 (H-2b) 
origin) were pulsed with SIINFEKL peptide (10 μ g/ml), and control El4 cells (non-pulsed) were incubated at 
37 °C for 1 h. Lymphocytes harvested from the spleen of γ -spz immunized mice at days 7, 12, 20, or 32 p.i. were 
co-cultured with El4 cells pulsed or not for 4 h at 37 °C in the presence of 1:400 brefeldin A (GolgiPlug; BD 
Bioscience), 1:600 monensin (GolgiStop; BD Bioscience), and anti-CD107a-FITC, a marker of cytotoxic activ-
ity. Cells were then permeabilized and fixed using a Cytofix/Cytoperm kit (BD Biosciences) according to the 
manufacturer’s instructions and stained for intracellular cytokines using anti-IFN-γ -PE-Cy7, anti-TNF-α -Pacific 
Blue, and anti-IL-2-APC (clone JES6–5H4) at pre-determined concentrations. After staining, cells were washed, 
diluted and analyzed on a LSR II flow cytometer (BD Bioscience). Functional characterization is based on the 
capacity of these cells to simultaneously produce or not different cytokines and also express CD107a on the cell 
surface, which indicates cytotoxic activity. Polyfunctional analysis was done by Boolean combination of gates with 
FlowJo software, and the data were exported to PESTLE and SPICE software for analysis.
Data analysis. Each experiment was carried out using 4–6 animals per group (transferred mice with AT1R+/+ 
OT-I cells or AT1R−/− OT-I cells) for days 3, 7, 12, 20, and 32 p.i. Data are reported as the means ± SEM of 2–3 rep-
resentative and independent experiments with similar results. Data normality was checked by the Shapiro-Wilk 
test. Then, for normal distributions, differences between the two groups were compared by a two-tailed Student’s t 
test or Mann-Whitney test for non-normal distributions, using Prism 5 software (GraphPad Software, version 5). 
The log-rank (Mantel–Cox) test was used to compare the percentage survival. The level of significance was set 
at α = 0.05. Permutation tests of significance of polyfunctional distributions were done using SPICE software.
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